Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (541-550 of 869) with videos related to

Pageof 87
Sort By:
Cancer Research|July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.
Blood|July 24, 2010
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Ender Soydan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
American Journal of Hematology|June 2, 2011
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myelomaIrene M Ghobrial, Nikhil C Munshi, Brianna N Harris, et al.
Pageof 87

Showing results (541-550 of 869) with videos related to

Sort By:
Pageof 87
Cancer Research|July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.
Blood|July 24, 2010
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Ender Soydan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
American Journal of Hematology|June 2, 2011
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myelomaIrene M Ghobrial, Nikhil C Munshi, Brianna N Harris, et al.
Pageof 87